Aware Super Pty Ltd as trustee of Aware Super Buys New Shares in Cencora, Inc. (NYSE:COR)

Aware Super Pty Ltd as trustee of Aware Super acquired a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 16,719 shares of the company's stock, valued at approximately $3,756,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Whittier Trust Co. raised its holdings in Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after purchasing an additional 44 shares in the last quarter. Shepherd Financial Partners LLC grew its holdings in shares of Cencora by 0.9% during the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after purchasing an additional 46 shares during the last quarter. WASHINGTON TRUST Co lifted its holdings in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the last quarter. JFS Wealth Advisors LLC grew its stake in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the last quarter. Finally, Cullen Frost Bankers Inc. lifted its stake in Cencora by 1.1% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock valued at $1,003,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares in the company, valued at $85,680,732.63. The trade was a 4.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on COR shares. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Bank of America upped their price objective on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Finally, Wells Fargo & Company raised their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus price target of $284.55.

Cencora Price Performance

Cencora stock traded up $2.58 during mid-day trading on Friday, reaching $287.02. The company had a trading volume of 1,617,494 shares, compared to its average volume of 1,509,410. The stock's 50-day simple moving average is $264.00 and its 200-day simple moving average is $247.33. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $296.65. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company has a market capitalization of $55.66 billion, a P/E ratio of 40.83, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Cencora's dividend payout ratio is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.